Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia.

Altered expression of the Fas-Fas ligand apoptotic pathway leads to lymphoproliferative and autoimmune diseases. In lpr/lpr mice and children with autoimmune lymphoproliferative syndrome, defective apoptosis is due to Fas mutations. Large granular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disorder associated with rheumatoid arthritis. Leukemic LGLs are resistant to Fas-dependent apoptosis despite expressing high levels of Fas. Such resistance can be overcome by activating leukemic LGLs in vitro, suggesting inhibition of Fas signaling in leukemic cells. We report that sera from patients with LGL leukemia contain high levels of soluble Fas. Ten of these 33 patients with LGL leukemia also had rheumatoid arthritis. Cloning and sequencing revealed expression of multiple Fas messenger RNA variants in leukemic LGL. These Fas variants, including 3 newly described here, encode soluble Fas molecules. Supernatants from cells transfected with these Fas variants blocked Fas-dependent apoptosis of leukemic LGLs. These results suggest that blockade of Fas-signaling by soluble Fas may be a mechanism leading to apoptosis resistance in leukemic LGLs.

[1]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[2]  A. Abbas,et al.  The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. , 1994, Immunity.

[3]  T. Loughran,et al.  Clonal diseases of large granular lymphocytes. , 1993, Blood.

[4]  G. Fiucci,et al.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.

[5]  S. Nagata,et al.  Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. , 1995, The EMBO journal.

[6]  T. Yokota,et al.  Expression of the Fas ligand in cells of T cell lineage. , 1995, Journal of immunology.

[7]  P. Krammer,et al.  Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[8]  Thomas P. Loughran,et al.  Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte leukemia , 1998 .

[9]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[10]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[11]  F. Ramsdell,et al.  Fas and FasL in the homeostatic regulation of immune responses. , 1995, Immunology today.

[12]  L. Lanier,et al.  Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen. , 1986, Journal of immunology.

[13]  I. Cascino,et al.  Fas splicing variants and their effect on apoptosis. , 1996, Advances in experimental medicine and biology.

[14]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[15]  S. Nagata,et al.  Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. , 1995, International immunology.

[16]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[17]  A. Abbas,et al.  Die and Let Live: Eliminating Dangerous Lymphocytes , 1996, Cell.

[18]  S. Nagata,et al.  Fas and Fas ligand: lpr and gld mutations. , 1995, Immunology today.

[19]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[20]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[21]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[22]  P. Krammer,et al.  Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. , 1995, Blood.

[23]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[24]  J. Cleveland,et al.  Contenders in FasL/TNF death signaling , 1995, Cell.

[25]  G. Starace,et al.  An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. , 1996, Journal of immunology.

[26]  A. Abbas,et al.  Role of Fas-mediated cell death in the regulation of immune responses. , 1996, Current opinion in immunology.

[27]  Masato Tanaka,et al.  Expression of the functional soluble form of human fas ligand in activated lymphocytes. , 1995, The EMBO journal.

[28]  J. H. Liu,et al.  Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. , 1998, Blood.

[29]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.